Literature DB >> 32479664

A case series of Monoclonal Gammopathy of Undetermined Significance and COVID-19.

Jesus D Gonzalez-Lugo1, Lizamarie Bachier-Rodriguez1, Mendel Goldfinger1, Aditi Shastri1, R Alejandro Sica1, Kira Gritsman1, Vikas Mehta2, Rafi Kabarriti3, Sanjay Goel1, Amit Verma1, Ira Braunschweig1, Noah Kornblum1, Ioannis Mantzaris1.   

Abstract

Entities:  

Keywords:  COVID 19; Monoclonal Gammopathy of Undetermined Significance (MGUS); coronavirus

Mesh:

Year:  2020        PMID: 32479664      PMCID: PMC7300638          DOI: 10.1111/bjh.16906

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   8.615


× No keyword cloud information.
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre‐malignant clonal plasma cell disorder, with 25–30% life‐long risk of progression to multiple myeloma (MM). It is usually asymptomatic, but infrequently associated with several serious conditions, such as neuropathies, glomerulonephritis and acquired angioedema. Moreover, a higher risk of infection and deep venous thrombosis has been reported in patients with MGUS. , In recent studies of SARS‐CoV‐2 infection (COVID‐19) in cancer, a higher fatality rate was found, especially in haematologic malignancies. While not an overt haematologic malignancy, MGUS falls within the spectrum of plasma cell dyscrasias, and has the potential to disrupt immunity and coagulation. , Therefore, MGUS could affect the course and outcome of COVID‐19; however, such association remains unknown. We describe seven patients diagnosed with MGUS who tested positive for COVID‐19 from 18 March through 8 April, 2020, at Montefiore Health System, that was the epicentre of the COVID‐19 pandemic in the Bronx, New York (Table I). All cases were positive by real‐time reverse‐transcriptase polymerase chain reaction of nasopharyngeal swabs.
Table I

Baseline characteristics, laboratory findings and clinical course of COVID‐19 patients with MGUS.

Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7
Age (years)59668371817692
GenderMaleFemaleMaleMaleFemaleMaleMale
Race/EthnicityHispanicWhiteAAOtherAAHispanicAA
Comorbidities

DM

HTN

HTN

CLD

DM

HTN

CKD

HTN

DM

HTN

CLD

CKD

CHF

DM

HTN

CKD

DM

HTN

CKD

Dementia

Immunoglobulin SubtypeIgG KappaIgG LambdaIgA KappaIgM LambdaIgG LambdaIgA LambdaIgG Kappa
MGUS risk stratificationLow‐intermediateLowHigh‐intermediateLow‐intermediateLowLow‐intermediateLow‐intermediate
NH residentNoNoNoNoNoNoYes
Lab Tests
Haemoglobin, g/l
Prior to admission125127118135104125112
Minimum991158210781
Platelets, x109/l
Prior to admission389317210116282315191
Minimum15689185301141
ANC (x109/l)
Prior to admission6·46·42·91·24·32·21·1
Minimum1·25·32·32·80·3
ALC (x109/l)
Prior to admission3·91·33·41·31·01·61·1
Minimum creatinine, mg/dl0·21·60·60·40·4
Prior to admission0·80·71·60·92·21·21·1
Maximum D‐dimer, μg/ml0·82·772·9412·71·7
Maximum ferritin, ng/ml201·382·1420
Maximum CRP, mg/dl15255271575766
Maximum25·15·676·2
Clinical course
Hospital admissionNoYesYesNoYesYesYes
ICU admissionNoNoNoNoNoNoNo
IntubationNoNoNoNoNoNoNo
DialysisNoNoNoNoNoYesNo
LOS, days168112513
OutcomeRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredDeceased

AA: African American, ALC: Absolute Lymphocyte Count, ANC: Absolute Neutrophil Count, CHF: Congestive Heart Failure, CKD: Chronic Kidney Disease, CLD: Chronic Lung Disease, DM: Diabetes Mellitus, HTN: Hypertension, LOS: Length of stay, MGUS: Monoclonal Gammopathy of Undetermined Significance, NH: Nursing Home.

MGUS Risk Stratification per Mayo Clinic Criteria.

Baseline characteristics, laboratory findings and clinical course of COVID‐19 patients with MGUS. DM HTN HTN CLD DM HTN CKD DM HTN CLD CKD CHF DM HTN CKD DM HTN CKD Dementia AA: African American, ALC: Absolute Lymphocyte Count, ANC: Absolute Neutrophil Count, CHF: Congestive Heart Failure, CKD: Chronic Kidney Disease, CLD: Chronic Lung Disease, DM: Diabetes Mellitus, HTN: Hypertension, LOS: Length of stay, MGUS: Monoclonal Gammopathy of Undetermined Significance, NH: Nursing Home. MGUS Risk Stratification per Mayo Clinic Criteria. Case 1: A 59‐year‐old Hispanic man with low‐ to intermediate‐risk IgG‐kappa MGUS, diabetes mellitus (DM) and hypertension (HTN), presented to the Emergency Department (ED) with three days of dry cough, subjective fever and myalgias. He was normotensive, afebrile, with a room‐air oxygen saturation (SpO2) of 98%. He did not require hospital admission, was followed‐up one month later and his symptoms had resolved. Case 2: A 66‐year‐old Caucasian woman with low‐risk IgG‐lambda MGUS, HTN and bronchiectasis presented to the ED with one week of productive cough, subjective fever, wheezing and diarrhoea. She was normotensive, febrile to 38.9°C, with a room‐air SpO2 of 98%. Her chest X‐ray (CXR) showed chronic changes. She was hospitalized, started on broad‐spectrum antibiotics for presumed superimposed pneumonia, and a course of hydroxychloroquine and lopinavir/ritonavir per institutional protocol. Her hospitalization was complicated by non‐infectious diarrhoea, which eventually improved, and was discharged to a rehabilitation facility after a 16‐day hospitalization. Case 3: An 83‐year‐old African American (AA) man with high‐ to intermediate‐risk IgA‐kappa MGUS, HTN, DM and chronic kidney disease (CKD), presented with altered mental status (AMS) and lethargy noticed a few hours prior to presentation, and six days of dry cough and malaise. He was normotensive, afebrile, with a room‐air SpO2 of 80%, which corrected to 96% on a nasal cannula (NC) (4 l/min). His CXR revealed multifocal bilateral infiltrates. Serum glucose was 884 mg/dl. He was started on intravenous fluids and insulin for his hyperosmolar hyperglycaemic state. D‐dimers peaked at 20 μg/ml. He received broad‐spectrum antibiotics for potential bacterial superinfection. His confusion gradually resolved, oxygen requirements improved and he was discharged home on hospital day eight. Case 4: A 71‐year‐old man with low‐ to intermediate‐risk IgM‐lambda MGUS and HTN presented to his general practitioner’s office with dry cough. He was instructed to self‐isolate at home, was followed‐up one month later and noted his symptoms had resolved. Case 5: An 81‐year‐old AA woman with low‐risk IgG‐lambda MGUS, HTN, DM, CKD, congestive heart failure, and pulmonary sarcoidosis presented to the ED with 10 days of dry cough and dyspnoea. She was hypotensive (90/53), afebrile, with a room‐air SpO2 of 89% which improved to 99% on a non‐rebreather mask (NRB). CXR showed left lung base atelectasis. Acute kidney injury (AKI) was noted. She was hospitalized, started on intravenous fluids with resolution of hypotension, and treated with hydroxychloroquine per institutional protocol. She was transitioned to NC on hospital day 2. Her renal function and oxygenation gradually improved, and she was discharged to a rehabilitation facility after an 11‐day hospitalization. Case 6: A 76‐year‐old Hispanic man with low‐ to intermediate‐risk IgA‐lambda MGUS, HTN, DM and CKD presented to the ED with five days of dry cough and dyspnoea. He was hypertensive (181/78 mm Hg), febrile (38.3°C), with a room‐air SpO2 of 96%. His CXR showed bibasilar infiltrates. AKI with hyperkalaemia was noted. He was hospitalized and later developed non‐ST‐elevation myocardial infarction, managed conservatively. His renal function deteriorated and on hospital day 6 haemodialysis was initiated. His renal function gradually improved and he was discharged home on hospital day 25. Case 7: A 92‐year‐old AA man, nursing‐home‐resident with low‐ to intermediate‐risk IgG‐kappa MGUS, HTN, DM, CKD, epilepsy and dementia presented to the ED with AMS and lethargy noticed a few hours prior to presentation. He had a dry cough, dyspnoea and malaise for one week. He was hypertensive (158/88 mm Hg), afebrile, with a room‐air SpO2 of 96%. On examination he was using accessory respiratory muscles. The patient had do‐not‐resuscitate and do‐not‐intubate orders and was therefore placed on a NRB. his CXR showed left mid‐lower lobe infiltrates. He was admitted, started on broad‐spectrum antibiotics and additionally treated for decompensated heart failure. D‐dimers peaked at 20 μg/ml. Finally, his family opted for comfort care and he expired on hospital day 13. COVID‐19 is a heterogeneous disease that ranges from asymptomatic in some patients to fatal in others. Advanced age, male sex and comorbidities, such as HTN and DM have been identified as risk factors for adverse prognosis. Significant coagulopathy has been observed in severe cases, and elevated D‐dimer levels have been shown to have prognostic significance. , , , , In a study performed at our institution, patients with haematologic malignancies and COVID‐19 had a higher mortality rate than non‐cancer patients. We wanted to investigate the effects that MGUS might have on patients with COVID‐19. Our patients were older adults with an age range between 59 and 92 years. They all had underlying conditions, identified as high‐risk comorbidities, yet none of the patients required mechanical ventilation or ICU management, and with the exception of one fatality, they all eventually recovered (Table I). The only fatality was a patient with multiple risk factors, including male sex, advanced age, nursing home residency, multiple comorbidities and a very elevated D‐dimer. MGUS represents the earliest stage of plasma cell dyscrasia and is generally an asymptomatic phase of the disease spectrum. Still, some studies suggest MGUS patients manifest increased susceptibility to bacterial and viral infections, as well as coagulation abnormalities. , Whether these perturbations of immunity and coagulation have the potential to impact the clinical trajectory of COVID‐19 remains to be examined with large‐scale data. This small case series seems to suggest that MGUS may not pose additional risks for poor outcome in COVID‐19 infection.

Conflicts of interest

The authors declare no competing financial interests.

Author contributions

AV, NK and IM conceived the research; AV, VM, RK, LBR, MG, AS, RAS, KG, IB and SJ identified the cases and provided clinical information; JGL collected the data; JGL, NK, IM and AV wrote the manuscript. All the authors reviewed and approved the final version of the manuscript.
  11 in total

1.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Authors:  Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

Review 2.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

Review 3.  Pathogenesis and progression of monoclonal gammopathy of undetermined significance.

Authors:  J Bladé; L Rosiñol; M T Cibeira; C F de Larrea
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

4.  Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sigurdur Y Kristinsson; Thomas R Fears; Gloria Gridley; Ingemar Turesson; Ulf-Henrik Mellqvist; Magnus Björkholm; Ola Landgren
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

5.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.

Authors:  Mengyuan Dai; Dianbo Liu; Miao Liu; Fuxiang Zhou; Guiling Li; Zhen Chen; Zhian Zhang; Hua You; Meng Wu; Qichao Zheng; Yong Xiong; Huihua Xiong; Chun Wang; Changchun Chen; Fei Xiong; Yan Zhang; Yaqin Peng; Siping Ge; Bo Zhen; Tingting Yu; Ling Wang; Hua Wang; Yu Liu; Yeshan Chen; Junhua Mei; Xiaojia Gao; Zhuyan Li; Lijuan Gan; Can He; Zhen Li; Yuying Shi; Yuwen Qi; Jing Yang; Daniel G Tenen; Li Chai; Lorelei A Mucci; Mauricio Santillana; Hongbing Cai
Journal:  Cancer Discov       Date:  2020-04-28       Impact factor: 39.397

6.  Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.

Authors:  Louise Bowles; Sean Platton; Nada Yartey; Minal Dave; Kurtis Lee; Daniel P Hart; Vickie MacDonald; Laura Green; Suthesh Sivapalaratnam; K John Pasi; Peter MacCallum
Journal:  N Engl J Med       Date:  2020-05-05       Impact factor: 91.245

7.  Covid-19 - Navigating the Uncharted.

Authors:  Anthony S Fauci; H Clifford Lane; Robert R Redfield
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.

Authors:  Vikas Mehta; Sanjay Goel; Rafi Kabarriti; Balazs Halmos; Amit Verma; Daniel Cole; Mendel Goldfinger; Ana Acuna-Villaorduna; Kith Pradhan; Raja Thota; Stan Reissman; Joseph A Sparano; Benjamin A Gartrell; Richard V Smith; Nitin Ohri; Madhur Garg; Andrew D Racine; Shalom Kalnicki; Roman Perez-Soler
Journal:  Cancer Discov       Date:  2020-05-01       Impact factor: 38.272

9.  Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis.

Authors:  Bolin Wang; Ruobao Li; Zhong Lu; Yan Huang
Journal:  Aging (Albany NY)       Date:  2020-04-08       Impact factor: 5.682

10.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

View more
  10 in total

1.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2020-06-27       Impact factor: 9.079

2.  Severe Anemia Due to Cold Agglutinin Syndrome in a COVID-19 Patient with IgM Monoclonal Gammopathy of Undetermined Significance Successfully Treated with Corticosteroids.

Authors:  Yutaka Tsukamoto; Masataka Umeda; Yuko Muto; Takashi Sugimoto; Momoko Yamauchi; Koji Ando; Koya Ariyoshi
Journal:  Intern Med       Date:  2022-03-26       Impact factor: 1.282

Review 3.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2021-01-27       Impact factor: 20.999

4.  COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients.

Authors:  Jennifer A Belsky; Brian P Tullius; Margaret G Lamb; Rouba Sayegh; Joseph R Stanek; Jeffery J Auletta
Journal:  J Infect       Date:  2021-02-04       Impact factor: 6.072

5.  The psychosocial impact of the COVID-19 pandemic on patients with monoclonal gammopathy of undermined significance, smouldering and active myeloma: findings from an international survey.

Authors:  Stephen J Quinn; Lesley A Anderson; Lynne Lohfeld; Charlene M McShane
Journal:  Br J Haematol       Date:  2021-06-21       Impact factor: 8.615

6.  Pattern of serum protein capillary electrophoretogram in SARS- CoV-2 infection.

Authors:  Surbhi Garg; Vijay Kumar Singh; Subash Chandra Sonkar; Harshit Kelkar; Shlesh Singh; Sandeep Garg; Mona Arya; Farah Husain; Lal Chandra; Anubhuti Chitkara; Tanmaya Talukdar; Binita Goswami; Bidhan Chandra Koner
Journal:  Clin Chim Acta       Date:  2022-01-07       Impact factor: 3.786

7.  Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.

Authors:  Saemundur Rognvaldsson; Elias Eythorsson; Sigrun Thorsteinsdottir; Brynjar Vidarsson; Pall Torfi Onundarson; Bjarni A Agnarsson; Margret Sigurdardottir; Ingunn Thorsteinsdóttir; Isleifur Olafsson; Hrafnhildur L Runolfsdottir; Dadi Helgason; Arna R Emilsdottir; Arnar S Agustsson; Aron H Bjornsson; Gudrun Kristjansdottir; Asdis Rosa Thordardottir; Olafur Skuli Indridason; Asbjorn Jonsson; Gauti Kjartan Gislason; Andri Olafsson; Hlif Steingrimsdottir; Petros Kampanis; Malin Hultcrantz; Brian G M Durie; Stephen Harding; Ola Landgren; Runolfur Palsson; Thorvarður Jon Love; Sigurdur Yngvi Kristinsson
Journal:  Blood Cancer J       Date:  2021-12-01       Impact factor: 11.037

8.  Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study.

Authors:  Nicola Sgherza; Paola Curci; Rita Rizzi; Vanda Strafella; Daniela Di Gennaro; Angelantonio Vitucci; Antonio Palma; Antonella Vita Russo Rossi; Francesco Albano; Pasquale Stefanizzi; Silvio Tafuri; Pellegrino Musto
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941

9.  COVID-19 Virus Infection in Three Patients With Hypogammaglobulinemia.

Authors:  Quinto Gesiotto; Asima Cheema; Kishan Avaiya; Bijal Shah; John Greene
Journal:  Cureus       Date:  2021-05-26

10.  Biclonal gammopathay in a case of severe COVID-19.

Authors:  Pooja Vashistha; Ajay Kumar Gupta; Mona Arya; Vijay Kumar Singh; Abhishek Dubey; Bidhan Chandra Koner
Journal:  Clin Chim Acta       Date:  2020-11-04       Impact factor: 3.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.